Alterity Therapeutics Limited (ATHE)

NASDAQ: ATHE · IEX Real-Time Price · USD
3.81
-0.14 (-3.54%)
At close: Feb 7, 2023, 3:52 PM
3.97
+0.16 (4.20%)
After-hours: Feb 7, 2023, 4:00 PM EST
-3.54%
Market Cap 16.61M
Revenue (ttm) n/a
Net Income (ttm) -8.92M
Shares Out 4.36M
EPS (ttm) -2.21
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 14,766
Open 3.94
Previous Close 3.95
Day's Range 3.81 - 3.95
52-Week Range 2.90 - 10.00
Beta 0.90
Analysts n/a
Price Target n/a
Earnings Date n/a

About ATHE

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing PBT2 that has completed Phase IIa clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limi... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1997
Employees 12
Stock Exchange NASDAQ
Ticker Symbol ATHE
Full Company Profile

Financial Performance

Financial numbers in AUD Financial Statements

News

Appendix 4C - Q2 FY23 Quarterly Cash Flow Report

Highlights: Expanded participation in ATH434 Phase 2 clinical trial with sites opened for recruitment in Australia, the United States, and Italy Presented compelling bioMUSE data at two prestigious in...

1 week ago - PRNewsWire

Alterity's ATH434 Prevents Loss of Brain Cells in Parkinson's Disease Animal Model

Independent Study Reports ATH434 Prevented Onset of Motor and Non-Motor Symptoms in Animals with Genetically Induced Parkinson's disease Independent Study Reports ATH434 Prevented Onset of Motor and N...

1 week ago - GlobeNewsWire

Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial in Italy for the Treatment of Individuals with Multiple System Atrophy

Recruitment ongoing in Europe, Asia-Pacific, and the U.S. for study of rapidly progressive Parkinsonian Disorder Recruitment ongoing in Europe, Asia-Pacific, and the U.S. for study of rapidly progress...

1 week ago - GlobeNewsWire

Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial in the United States for the Treatment of Individuals with Multiple System Atrophy

U.S. now open for enrollment  of rare, rapidly progressive Parkinsonian Disorder MELBOURNE, Australia and SAN FRANCISCO , Jan. 9, 2023 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("...

1 month ago - PRNewsWire

Alterity Therapeutics Announces 1-for-10 Reverse ADS Split (consolidation)

MELBOURNE, Australia and SAN FRANCISCO , Jan. 6, 2023 /PRNewswire/ -- Alterity Therapeutics Limited ("Alterity" or the "Company") (ASX:ATH, NASDAQ:ATHE), a biotechnology company dedicated to developin...

1 month ago - PRNewsWire

Alterity Therapeutics to Participate in the Sachs Associates 6th Annual Neuroscience Innovation Forum

MELBOURNE, Australia and SAN FRANCISCO, Jan. 3, 2023 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disea...

1 month ago - PRNewsWire

Alterity Therapeutics Announces Allowance of New Composition of Matter Patent by the United States Patent and Trademark Office

- Patent covers more than 100 novel compounds targeting neurodegenerative diseases including Parkinson's and Alzheimer's - MELBOURNE, Australia and SAN FRANCISCO , Dec. 29, 2022 /PRNewswire/ -- Alteri...

1 month ago - PRNewsWire

Alterity Therapeutics Announces Presentation of Data from the bioMUSE Natural History Study at the American Autonomic Society Annual Meeting

MELBOURNE, Australia and SAN FRANCISCO , Nov. 7, 2022 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing dise...

3 months ago - PRNewsWire

Appendix 4C - Q1 FY23 Quarterly Cash Flow Report

First patient dosed in Phase 2 clinical trial for ATH434 in New Zealand, trial opens in Europe and Australia Approval of Investigational New Drug application by FDA to bring the Phase 2 clinical trial...

3 months ago - PRNewsWire

Alterity Therapeutics Announces Presentation of MRI Data from the bioMUSE Natural History Study at the American Neurological Association Annual Meeting

MELBOURNE, Australia and SAN FRANCISCO , Oct. 26, 2022 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing dis...

3 months ago - PRNewsWire

Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial in Australia for the Treatment of Individuals with Multiple System Atrophy

Australia now open for study of rare, rapidly progressive Parkinsonian Disorder MELBOURNE, Australia and SAN FRANCISCO , Oct. 13, 2022 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("...

4 months ago - PRNewsWire

Alterity Therapeutics Announces Presentation of Wearable Sensor Data from the bioMUSE Natural History Study at the International Congress of Parkinson's Disease and Movement Disorders

- Wearable sensors strongly correlated with clinical scales on motor impairment - - bioMUSE Study Validates Use of Wearable Sensors for Alterity's Ongoing Phase 2 Clinical Trial - MELBOURNE, Australia...

4 months ago - PRNewsWire

Alterity Therapeutics Receives U.S. FDA Approval for Investigational New Drug Application for ATH434 for the Treatment of Multiple System Atrophy

Regulatory Authorization Granted to Proceed with ATH434 Phase 2 Clinical Trial MELBOURNE, Australia and SAN FRANCISCO , Sept. 20, 2022 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("...

5 months ago - PRNewsWire

Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial for the Treatment of Patients with Multiple System Atrophy in Europe

Second region now open for enrolment for rare, rapidly progressive, neurodegenerative disease MELBOURNE, Australia and SAN FRANCISCO , Aug. 25, 2022 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NA...

5 months ago - PRNewsWire

Alterity Therapeutics: Appendix 4C - Q4 FY22 Quarterly Cash Flow Report

Phase 2 clinical trial for ATH434 commences in New Zealand and patient enrolment begins Regulatory approval from the U.K. and Italian regulatory agencies to proceed with the Phase 2 trial A$4.1 millio...

7 months ago - PRNewsWire

Alterity Therapeutics Doses First Patient in ATH434 Phase 2 Clinical Trial in Multiple System Atrophy

MELBOURNE, Australia and SAN FRANCISCO , July 6, 2022 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing dise...

7 months ago - PRNewsWire

Alterity Therapeutics Announces Regulatory Authorization to Proceed with ATH434 Phase 2 Clinical Trial in Italy

MELBOURNE, Australia and SAN FRANCISCO, June 23, 2022 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing dise...

8 months ago - PRNewsWire

Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial for the Treatment of Patients with Multiple System Atrophy

Multiple System Atrophy is a rare, rapidly progressive, neurodegenerative disease that causes profound disability MELBOURNE, Australia , June 2, 2022 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, N...

8 months ago - PRNewsWire

Alterity Therapeutics Announces Regulatory Authorization to Proceed with ATH434 Phase 2 Clinical Trial in the United Kingdom

MELBOURNE, Australia , April 27, 2022 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying tr...

10 months ago - PRNewsWire

Alterity Therapeutics Announces Presentation of bioMUSE Data at the American Academy of Neurology (AAN) Annual Meeting

The data provides further validation of the intended Phase 2 study design MELBOURNE, Australia and SAN FRANCISCO , April 6, 2022 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alteri...

10 months ago - PRNewsWire

Alterity Therapeutics to Present at the 34th Annual Roth Conference

MELBOURNE, Australia and SAN FRANCISCO, March 7, 2022 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing dise...

1 year ago - PRNewsWire

Alterity Therapeutics Highlights New Publications On ATH434 In Parkinson's Disease

Alterity Therapeutics's ATHE data in an animal model of Multiple System Atrophy (MSA) were published in the Journal of Parkinson's Disease.  [ALERT[ Matt Maley just released his latest pick with an up...

1 year ago - Benzinga

Alterity Therapeutics Announces Publication Demonstrating that ATH434 is Neuroprotective in Animal Model of Parkinsonian Disorder in the Journal of Parkinson's Disease

MELBOURNE, Australia, Jan. 28, 2022 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying trea...

1 year ago - PRNewsWire

Appendix 4C - Q2 FY22 Quarterly Cash Flow Report

Highlights: NZ's regulator Medsafe authorizes Phase 2 clinical trial for ATH434; more jurisdictions to follow New poster presentation and publications provide further evidence of potential of ATH434 t...

1 year ago - PRNewsWire

Alterity Therapeutics Granted New US Patent for Compounds for Neurodegenerative Diseases Including Parkinson's and Alzheimer's

MELBOURNE, Australia and SAN FRANCISCO , Jan. 6, 2022 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing dise...

1 year ago - PRNewsWire